1 / 2

Plerixafor injection

Plerixafor is a cancer formulation that is sold under the brand name Mozifor. This medicine is used in the treatment of individuals with multiple myeloma or non-Hodgkin's lymphoma. It is given by a doctor as an injection under the skin (subcutaneously). Buy plerixafor injection at 30% off on Magicine Pharma.<br>

15032
Download Presentation

Plerixafor injection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Plerixafor injection Overview Plerixafor is a cancer formulation that is sold under the brand name Mozifor. This medicine is used in the treatment of individuals with multiple myeloma or non-Hodgkin's lymphoma. It is given by a doctor as an injection under the skin (subcutaneously). Buy plerixafor injection at 30% off on Magicine Pharma. Medicine details

  2. Brand name - Mozifor Generic name - Plerixafor Manufacturer - Hetero Drugs Ltd Salt composition - Plerixafor (24mg) Storage - Store at room temperature (10-30°C) Dosage form - Injection Strength - 1.2 ml Packaging - Vial Gender - Unisex Pharmacodynamics Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day was evaluated in two placebo-controlled clinical studies in patients with NHL and MM. The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis was noted. During this 24-hour period, a single dose of placebo was administered 10 to 11 hours prior to apheresis. Peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. A sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours.

More Related